Clinical trials: CTC
Estrogen Receptor Negative, Estrogen Receptor Positive
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
The purpose of the study is to evaluate the impact on progression-free survival (PFS) with the combination carboplatin - pembrolizumab in patients with CTC (circulating tumor cells) positive, HER2 negative metastatic breast…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT03213041
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Breast Cancer, Leptomeningeal Metastasis
Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer
This study will prospectively enroll 36 evaluable subjects with breast cancer who are undergoing workup for clinical suspicion of leptomeningeal metastasis (LM).
- Trial name
- NCT02948751
- Testing
- OncoCEE
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Columbia University
Breast Cancer
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00382018
- Testing
- chemotherapy
- Where
- 296 sites in United States
- Volunteers
- 624 people
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer
The National CT Colonography Trial
RATIONALE: New diagnostic procedures such as computed tomographic colonography may improve the ability to detect colorectal cancer and may provide a less invasive method of detection.
- Trial name
- ACRIN6664 (NCT00084929)
- Testing
- CT Colonography
- Where
- 14 sites in United States
- Volunteers
- 2,600 people, healthy volunteers welcome
- Sponsor
- American College of Radiology Imaging Network
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
- Trial name
- MACS1295 (NCT01129336)
- Testing
- Zoledronic acid, Standard Therapy
- Where
- 33 sites in United States
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Spinal Disease
Anderson Circulating Tumor Cell Burden (CTCB) Study
Phase 1 - Optimization Phase: Primary Objective: The primary objective of Phase 1 of this study is to determine the time point at which maximal Circulating Tumor Cell Burden (CTCB) occurs following standard vertebroplasty and…
- Conditions
- Cancer, Spinal Disease, Vertebral Compression Fractures
- Trial name
- NCT00819832
- Testing
- Kyphoplasty, Vertebroplasty, Cavity SpineWand
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Patients With High-risk Prostate Cancer
Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy
The detection and quantification of Circulating tumor cells CTCs in peripheral blood of patients with prostate adenocarcinoma may be useful at least for: Getting a correct stratification of patients with high-risk prostate cancer…
- Trial name
- NCT01800058
- Where
- 3 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Breast Cancer, Metastatic Breast Cancer
Trastuzumab and Vinorelbine in Advanced Breast Cancer
The purpose of this research study is to see what effects trastuzumab in combination with vinorelbine has on breast cancer when the participant has circulating tumor cells that are positive for the protein called HER2.
- Trial name
- NCT01185509
- Testing
- trastuzumab, vinorelbine
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Metastatic Breast Carcinoma
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
The goal of this clinical research study is to learn the relationship of high-dose chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling metastatic breast cancer.
- Conditions
- Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
- Trial name
- NCT00429182
- Testing
- Carboplatin, Cyclophosphamide, Thiotepa
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy
CTC levels collected pre-surgery will be correlated with pathological samples.
- Trial name
- NCT02135679
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colorectal Cancer Screening
Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population.
The primary objective of this multicenter, prospective, randomized study is to assess the diagnostic yield of Colon Capsule Endoscopy (CCE) versus Computed Tomographic Colonography (CTC) in a screening population.
- Trial name
- TOPAZ (NCT02754661)
- Testing
- COLON Capsule endoscopy, Computed Tomographic Colonography
- Where
- 13 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Immune Evasion, Tumor, Neoplastic Cells, Circulating
Immune Mechanisms After Radiofrequency Ablation of Pulmonary Metastases From Colorectal Cancer Origin
Local percutaneous thermal ablation is frequently proposed in the management of metastatic diseases. Radiofrequency ablation (RFA) has demonstrated good results when the metastatic disease is limited and slowly evolving.
- Conditions
- Immune Evasion, Tumor, Neoplastic Cells, Circulating, Circulating Tumor Cell, Pulmonary Metastasis
- Trial name
- ARFIM (NCT03960021)
- Testing
- RFA interventions
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut Bergonié
Synchronous Metastasized Breast Cancer, Circulating Tumor Cells
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Primary Operation in synchronous metastasized invasive breast cancer to evaluate the use of local therapy
- Trial name
- POSYTIVE (NCT01015625)
- Testing
- Surgery, Surgery on Demand
- Where
- 14 sites in Austria
- Volunteers
- 90 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
The purpose of this study is to look at the amount of cancer cells in the blood of participants who are being treated with denosumab.
- Conditions
- Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count, Estrogen Receptor Positive, HER2/Neu Negative
- Trial name
- NCT03070002
- Testing
- Denosumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Prostate Cancer
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
The main objective of this study is to evaluate the effects of PLX3397 on male subjects with CRPC. Secondary objectives include evaluating the safety and tolerability of PLX3397 and the anti-tumor effects that PLX3397 has on the…
- Trial name
- NCT01499043
- Testing
- PLX3397
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Daiichi Sankyo
Prostate Cancer
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
This is a single arm study of 11 men with treatment refractory metastatic Castrate Resistant Prostate Cancer (CRPC) who will receive temsirolimus IV at a dose of 25 mg weekly until progression.
- Trial name
- NCT00887640
- Testing
- Temsirolimus, Diphenhydramine
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Duke University